FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148451359> ?p ?o ?g. }

• W2148451359 endingPage "680" @default.
• W2148451359 startingPage "674" @default.
• W2148451359 abstract "The purpose of this prospective study was to characterize the clinical profile of patients with atrial fibrillation (AF) in cardiology practice and to assess how successfully guidelines have been implemented in real-world practice. This prospective study involved 23 cardiologists established in office practice in Geneva. Enrolment started on 1 January 2005 and ended on 31 December 2005. Consecutive patients were included if they were >18 years and had AF documented on an ECG during the index office visit or during the preceding month. In this survey, 622 ambulatory patients were enrolled (390 males and 232 females; mean age 69.8 ± 11.8 years). The prevalence of paroxysmal, persistent, and permanent AF was 35, 18, and 47%, respectively. Underlying cardiac disorders present in 513 patients (82%) included hypertensive heart disease (30%), valvular heart disease (27%), coronary artery disease (18%), and myocardial disease (11%). A rate-control strategy was chosen in 53% of the patients (331/622). The mean CHADS 2 score was 1.43 ± 1.24, and 458/622 patients (73.6%) had a CHADS 2 score ≥1. Among patients with an indication to oral anticoagulant therapy (OAT), 88% (403/458) effectively received it. The rate of OAT was closely correlated with an increasing CHADS 2 score, particularly with patients age (72, 81, and 87% for patients <65, 65–75, and >75 years of age, respectively). True contraindication for OAT was present in 4% (18/458). In the low-risk group (CHADS 2 score = 0), 58% were prescribed OAT, but in 37% of them only for a short period of time (cardioversion/ablation). After a follow-up of 396 ± 109 days, 72% of the study group (410/570) was still treated by OAT. During follow-up, 23/570 patients died (4%), essentially from a cardiovascular cause (15/23), 15 had a non-lethal embolic stroke (2.7%), and 8 had significant bleeding complications (1.5%). This study shows one of the highest OAT prescription rates for AF reported until now and demonstrates how successfully guidelines can be applied in the real world. A definite overinterpretation of current guidelines is observed in low-risk patients with AF. True contraindication for OAT (4%) and significant bleeding during OAT (1.5%) were rare." @default.
• W2148451359 created "2016-06-24" @default.
• W2148451359 creator A5016675379 @default.
• W2148451359 creator A5040553588 @default.
• W2148451359 creator A5045866571 @default.
• W2148451359 creator A5047165660 @default.
• W2148451359 date "2008-04-07" @default.
• W2148451359 modified "2023-09-27" @default.
• W2148451359 title "Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world" @default.
• W2148451359 cites W1969012171 @default.
• W2148451359 cites W19748391 @default.
• W2148451359 cites W1988128773 @default.
• W2148451359 cites W2000398770 @default.
• W2148451359 cites W2001473873 @default.
• W2148451359 cites W2004375989 @default.
• W2148451359 cites W2007280418 @default.
• W2148451359 cites W2010839357 @default.
• W2148451359 cites W2032385515 @default.
• W2148451359 cites W2057221195 @default.
• W2148451359 cites W2060527467 @default.
• W2148451359 cites W2060630424 @default.
• W2148451359 cites W2062786076 @default.
• W2148451359 cites W2064428105 @default.
• W2148451359 cites W2066098573 @default.
• W2148451359 cites W2074119210 @default.
• W2148451359 cites W2097156473 @default.
• W2148451359 cites W2105486760 @default.
• W2148451359 cites W2110253 @default.
• W2148451359 cites W2128240892 @default.
• W2148451359 cites W2144582288 @default.
• W2148451359 cites W2161283927 @default.
• W2148451359 cites W2164609466 @default.
• W2148451359 cites W2164641554 @default.
• W2148451359 cites W2169233115 @default.
• W2148451359 cites W2180920440 @default.
• W2148451359 cites W2260482868 @default.
• W2148451359 doi "https://doi.org/10.1093/europace/eun086" @default.
• W2148451359 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18403385" @default.
• W2148451359 hasPublicationYear "2008" @default.
• W2148451359 type Work @default.
• W2148451359 sameAs 2148451359 @default.
• W2148451359 citedByCount "59" @default.
• W2148451359 countsByYear W21484513592012 @default.
• W2148451359 countsByYear W21484513592013 @default.
• W2148451359 countsByYear W21484513592014 @default.
• W2148451359 countsByYear W21484513592015 @default.
• W2148451359 countsByYear W21484513592016 @default.
• W2148451359 countsByYear W21484513592017 @default.
• W2148451359 countsByYear W21484513592018 @default.
• W2148451359 countsByYear W21484513592019 @default.
• W2148451359 countsByYear W21484513592021 @default.
• W2148451359 crossrefType "journal-article" @default.
• W2148451359 hasAuthorship W2148451359A5016675379 @default.
• W2148451359 hasAuthorship W2148451359A5040553588 @default.
• W2148451359 hasAuthorship W2148451359A5045866571 @default.
• W2148451359 hasAuthorship W2148451359A5047165660 @default.
• W2148451359 hasBestOaLocation W21484513591 @default.
• W2148451359 hasConcept C126322002 @default.
• W2148451359 hasConcept C142724271 @default.
• W2148451359 hasConcept C164705383 @default.
• W2148451359 hasConcept C1862650 @default.
• W2148451359 hasConcept C187212893 @default.
• W2148451359 hasConcept C188816634 @default.
• W2148451359 hasConcept C204787440 @default.
• W2148451359 hasConcept C2776494729 @default.
• W2148451359 hasConcept C2778213512 @default.
• W2148451359 hasConcept C2779161974 @default.
• W2148451359 hasConcept C2779736815 @default.
• W2148451359 hasConcept C2779974597 @default.
• W2148451359 hasConcept C35785553 @default.
• W2148451359 hasConcept C71924100 @default.
• W2148451359 hasConceptScore W2148451359C126322002 @default.
• W2148451359 hasConceptScore W2148451359C142724271 @default.
• W2148451359 hasConceptScore W2148451359C164705383 @default.
• W2148451359 hasConceptScore W2148451359C1862650 @default.
• W2148451359 hasConceptScore W2148451359C187212893 @default.
• W2148451359 hasConceptScore W2148451359C188816634 @default.
• W2148451359 hasConceptScore W2148451359C204787440 @default.
• W2148451359 hasConceptScore W2148451359C2776494729 @default.
• W2148451359 hasConceptScore W2148451359C2778213512 @default.
• W2148451359 hasConceptScore W2148451359C2779161974 @default.
• W2148451359 hasConceptScore W2148451359C2779736815 @default.
• W2148451359 hasConceptScore W2148451359C2779974597 @default.
• W2148451359 hasConceptScore W2148451359C35785553 @default.
• W2148451359 hasConceptScore W2148451359C71924100 @default.
• W2148451359 hasIssue "6" @default.
• W2148451359 hasLocation W21484513591 @default.
• W2148451359 hasLocation W21484513592 @default.
• W2148451359 hasOpenAccess W2148451359 @default.
• W2148451359 hasPrimaryLocation W21484513591 @default.
• W2148451359 hasRelatedWork W1969060188 @default.
• W2148451359 hasRelatedWork W2002034594 @default.
• W2148451359 hasRelatedWork W2050495877 @default.
• W2148451359 hasRelatedWork W2127690875 @default.
• W2148451359 hasRelatedWork W2284869607 @default.
• W2148451359 hasRelatedWork W2409916269 @default.
• W2148451359 hasRelatedWork W2955492843 @default.
• W2148451359 hasRelatedWork W3028901408 @default.

• next